Age-related common miRNA polymorphism associated with severe toxicity in lung cancer patients treated with platinum-based chemotherapy

被引:18
|
作者
Fang, Chao [1 ,2 ]
Li, Xiang-Ping [3 ]
Gong, Wei-Jing [1 ,2 ]
Wu, Na-Yiyuan [1 ,2 ]
Tang, Jie [1 ,2 ]
Yin, Ji-Ye [1 ,2 ]
Li, Xi [1 ,2 ]
Zhang, Wei [1 ,2 ]
Zhou, Hong-Hao [1 ,2 ,4 ]
Liu, Zhao-Qian [1 ,2 ,4 ]
机构
[1] Cent S Univ, Xiangya Hosp, Dept Clin Pharmacol, Changsha, Hunan, Peoples R China
[2] Cent S Univ, Hunan Key Lab Pharmacogenet, Inst Clin Pharmacol, Changsha, Hunan, Peoples R China
[3] Cent S Univ, Dept Pharm, Xiangya Hosp, Changsha, Hunan, Peoples R China
[4] Hunan Prov Cooperat Innovat Ctr Mol Target New Dr, Hengyang, Peoples R China
基金
中国国家自然科学基金;
关键词
lung cancer; miRNA; platinum-based chemotherapy; polymorphism; toxicity; FUNCTIONAL POLYMORPHISM; HIGH-RISK; MICRORNAS; SUSCEPTIBILITY; BIOMARKERS; MIR-146A; EXPRESSION; SURVIVAL; MIR-27; GENES;
D O I
10.1111/1440-1681.12704
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Platinum-based chemotherapy toxicity severely impedes successful treatment in lung cancer patients. MicroRNAs (miRs) have a significant impact on the occurrence and survival rate of lung cancer. The purpose of this study was to investigate the association between common miRNA variants and platinum-based chemotherapy toxicity in lung cancer patients. A total of eight functional single nucleotide polymorphisms (SNPs) of miRNA were genotyped in 408 lung cancer patients by MALDI-TOF mass spectrometry. All the patients were histologically confirmed as lung cancer, and were treated with platinum-based chemotherapy for at least two cycles. It was found that the polymorphism rs2042553 of miR-5197 had a significant association with overall severe toxicity in both additive (P=.031, odds ratio [OR]=1.41, 95% confidence interval [CI] 1.03-1.93) and dominant (P=.009, OR=1.80, 95% CI 1.16-2.80) models. MiR-605 rs2043556 was significantly related to severe hepatotoxicity in dominant model (P=.022, OR=2.51, 95% CI 1.12-4.14). In addition, rs2910164 of miR-146a had marginal statistical effect on severe hepatotoxicity in additive model (P=.054). The subgroup analyses showed that miR-27a rs895819 was related to gastrointestinal toxicity in age >56years old, smoking and non-smoking patients. Taken together, our results revealed that polymorphisms of miR-5197, miR-605, miR-146a, and miR-27a contributed to the chemotherapy toxicity of lung cancer, which may serve as a predictive tool for toxicity evaluation of platinum-based chemotherapy in lung cancer patients.
引用
收藏
页码:21 / 29
页数:9
相关论文
共 50 条
  • [21] Weight Loss Associated with Platinum-Based Chemotherapy in Patients with Advanced Lung Cancer
    Morio, Kayoko
    Minami, Toshiyuki
    Sozu, Takashi
    Niki, Kazuyuki
    Kijima, Takashi
    Uejima, Etsuko
    CHEMOTHERAPY, 2015, 61 (05) : 256 - 261
  • [22] Association of p53 codon 72 polymorphism and survival of North Indian lung cancer patients treated with platinum-based chemotherapy
    Ankita Kumari
    Charu Bahl
    Navneet Singh
    Digambar Behera
    Siddharth Sharma
    Molecular Biology Reports, 2016, 43 : 1383 - 1394
  • [23] The Association Between Heat-Shock Protein Polymorphisms and Prognosis in Lung Cancer Patients Treated With Platinum-Based Chemotherapy
    Zou, Ting
    Liu, Jun-Yan
    She, Li
    Yin, Ji-Ye
    Li, Xi
    Li, Xiang-Ping
    Zhou, Hong-Hao
    Chen, Juan
    Liu, Zhao-Qian
    FRONTIERS IN PHARMACOLOGY, 2020, 11
  • [24] Genome-wide examination of genetic variants associated with response to platinum-based chemotherapy in patients with small-cell lung cancer
    Wu, Chen
    Xu, Binghe
    Yuan, Peng
    Ott, Jurg
    Guan, Yin
    Liu, Yu
    Liu, Zhe
    Shen, Yuanyuan
    Yu, Dianke
    Lin, Dongxin
    PHARMACOGENETICS AND GENOMICS, 2010, 20 (06) : 389 - 395
  • [25] CAMSAP1 Mutation Correlates With Improved Prognosis in Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy
    Yi, Yonglin
    Qiu, Zhengang
    Yao, Zifu
    Lin, Anqi
    Qin, Yimin
    Sha, Ruizhan
    Wei, Ting
    Wang, Yanru
    Cheng, Quan
    Zhang, Jian
    Luo, Peng
    Shen, Weitao
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2022, 9
  • [26] Pharmacogenetics of the DNA repair pathways in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy
    Sullivan, Ivana
    Salazar, Juliana
    Majem, Margarita
    Pallares, Cinta
    del Rio, Elisabeth
    Paez, David
    Baiget, Montserrat
    Barnadas, Agusti
    CANCER LETTERS, 2014, 353 (02) : 160 - 166
  • [27] Sequence Variation in Mature MicroRNA-499 Confers Unfavorable Prognosis of Lung Cancer Patients Treated with Platinum-Based Chemotherapy
    Qiu, Fuman
    Yang, Lei
    Ling, Xiaoxuan
    Yang, Rongrong
    Yang, Xiaorong
    Zhang, Lisha
    Fang, Wenxiang
    Xie, Chenli
    Huang, Dongsheng
    Zhou, Yifeng
    Lu, Jiachun
    CLINICAL CANCER RESEARCH, 2015, 21 (07) : 1602 - 1613
  • [28] The Effects of WISP1 Polymorphisms on the Prognosis of Lung Cancer Patients with Platinum-Based Chemotherapy
    He, Jia
    Wang, Zhan
    Wang, Ying
    Zou, Ting
    Li, Xiang-Ping
    Cao, Lei
    Chen, Juan
    PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2021, 14 : 1193 - 1203
  • [29] Association of well-characterized lung cancer lncRNA polymorphisms with lung cancer susceptibility and platinum-based chemotherapy response
    Gong, Wei-Jing
    Yin, Ji-Ye
    Li, Xiang-Ping
    Fang, Chao
    Xiao, Di
    Zhang, Wei
    Zhou, Hong-Hao
    Li, Xi
    Liu, Zhao-Qian
    TUMOR BIOLOGY, 2016, 37 (06) : 8349 - 8358
  • [30] ATP7B rs9535826 is associated with gastrointestinal toxicity of platinum-based chemotherapy in nonsmall cell lung cancer patients
    Li, Yue-Qin
    Zhang, Xin-Yin
    Chen, Juan
    Yin, Ji-Ye
    Li, Xiang-Ping
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2018, 14 (04) : 881 - 886